Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NEO PV 01

Drug Profile

NEO PV 01

Alternative Names: Neo Vax; NEO-PV-01; Neoantigen vaccine; Neoantigen-based vaccine - BioNTech; NeoAntigen-peptides; Personalized-neoantigen-cancer-vaccine-BioNTech; Personalized-neoantigen-vaccine-BioNTech

Latest Information Update: 28 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Broad Institute; Dana-Farber Cancer Institute
  • Developer BioNTech; Bristol-Myers Squibb; Celldex Therapeutics Inc; Dana-Farber Cancer Institute; Merck Sharp & Dohme; National Institutes of Health (USA); Neon Therapeutics; Oncovir; Washington University School of Medicine
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunoglobulin stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Malignant melanoma
  • No development reported Bladder cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

  • 28 Feb 2022 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Late-stage disease, Metastatic disease) in USA (Parenteral, Injection)
  • 28 Nov 2021 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, First-line therapy) in USA (Parenteral)
  • 08 Nov 2021 Washington University School of Medicine and National Cancer Institute plans a phase I trial for Adenocarcinoma (Newly-diagnosed, Combination therapy) in USA (IM) (NCT05111353)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top